Olgotrelvir, a dual inhibitor of SARS-CoV-2 M
pro
and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19
Med
.
2024 Feb 9;5(2):169-171.
doi: 10.1016/j.medj.2024.01.013.
Authors
Long Mao
,
Namir Shaabani
,
Xiaoying Zhang
,
Can Jin
,
Wanhong Xu
,
Christopher Argent
,
Yulia Kushnareva
,
Colin Powers
,
Karen Stegman
,
Jia Liu
,
Hui Xie
,
Changxu Xu
,
Yimei Bao
,
Lijun Xu
,
Yuren Zhang
,
Haigang Yang
,
Shengdian Qian
,
Yong Hu
,
Jianping Shao
,
Can Zhang
,
Tingting Li
,
Yi Li
,
Na Liu
,
Zhenhao Lin
,
Shanbo Wang
,
Chao Wang
,
Wei Shen
,
Yuanlong Lin
,
Dan Shu
,
Zhenhong Zhu
,
Olivia Kotoi
,
Lisa Kerwin
,
Qing Han
,
Ludmila Chumakova
,
John Teijaro
,
Mike Royal
,
Mark Brunswick
,
Robert Allen
,
Henry Ji
,
Hongzhou Lu
,
Xiao Xu
PMID:
38340710
DOI:
10.1016/j.medj.2024.01.013
No abstract available
Publication types
Published Erratum